This application relates to non-human primate (NHP) induced pluripotent stem cell (IPSC)-derived hepatocytes, for example, Cynomolgus monkey (Macaca fascicularis) induced pluripotent stem cell-derived hepatocytes, and methods of producing the same. Moreover, this application relates to methods of using NHP IPSC-derived hepatocytes for drug screening, drug safety assessment and in models of infection.

In related-art methods of differentiating pluripotent stem cells into a desired cell type, there has not been established a differentiation induction method using human ES/iPS cells and being stable and highly efficient. A method of inducing differentiation into a desired cell type within a short period of time and with high efficiency by attenuating differentiation resistance of a pluripotent stem cell to generate a pluripotent stem cell that actively proceeds to a differentiated cell type has been found, and thus the present invention has been completed.

Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.

There is disclosed patient derived xenograft (PDXs) cells/systems/models and/or derivatives, parental (unlabelled) and/or labelled, expressing a fluorescent protein or a luciferase, or a combination thereof; for evaluating therapies comprising nasopharyngeal carcinoma (EBV positive and/or EBV negative). In another embodiment, there is disclosed a method of evaluating the efficacy of an agent used to treat nasopharyngeal carcinoma (NPC) comprising: preparing a non-human model; whereby the non-human model carries cells from NPC xenograft; labelling the cells from the NPC xenograft with gfp-luc2 marker using a lentiviral vector system; and growing the cells in short term in vitro culture; including adaptation of said culture into multi-well plates for use in further screening and/or evaluation assays; wherein the NPC xenograft is PDX.

A method for reducing renal tissue toxicity in a subject caused by a kidney damaging agent is disclosed. The method comprises administering to the subject: (i) a kidney damaging agent; and (ii) an inhibitor of glucose reabsorption.

An object of the present invention is to provide an artificial tissue perfusion device capable of analyzing the interaction between a vascular cell layer and a parenchymal cell layer with high accuracy. An artificial tissue perfusion device includes a co-culture system (C) in which a plurality of types of cell are cultured. The co-culture system has a tubular well part (10) having a culture space (11) inside; a base material (20) having a perfusion flow path (26) which extends in a predetermined direction and is perfused with a medium, and a holding part (23) which opens to the perfusion flow path and holds the well part attachably and detachably; and a gel membrane (30) having a form of a porous membrane and disposed at an end portion of the well part facing the perfusion flow path in a case where the well part is held by the holding part. A tissue-based cell is cultured on a surface side of the gel membrane facing the culture space, and a luminal cell is cultured on a surface side of the gel membrane facing the perfusion flow path.

Systems and methods are provided including a housing configured to receive and engage a hollow tissue structure within a fluid chamber of the housing. A first pair of flow channels and a second pair of flow channels of the housing are fluidly coupled to the fluid chamber. The housing fluidly couples the first pair of flow channels and fluidly couples the second pair of flow channels via a second flow path such that a change in a fluid pressure differential between a first fluid in the first flow path and a second fluid in the second flow path deflects at least a portion of the hollow tissue structure causing a change in flow of the first fluid through the first pair of flow channels or a change in flow of the second fluid through the second pair of flow channels.

Systems and methods for identifying molecules that are biologically active against a disease, where the method can comprise culturing a first mammalian cell population under organoid formation conditions in the presence of a test molecule to obtain a first organoid, wherein the first mammalian cell population, when cultured under the organoid formation conditions in the absence of the test molecule, results in an organoid with a disease phenotype; imaging the first organoid following exposure to the test molecule; analyzing one or more images of the first organoid using a neural network that has been trained to assign a probability score of disease or non-disease ranging between 0% and 100%; assigning the first organoid a probability score ranging between 0% and 100%; wherein the test molecule is biologically active against the disease if the probability score of the first organoid is greater than a cutoff probability score of non-disease or lower than a cutoff probability score of disease.

Methods for obtaining populations of norepinephrine (NE) neuronal progenitor cells and creating enriched populations of NE neurons are provided herein. Also provided herein are methods for obtaining genetically modified NE neurons expressing a NE sensor or a TH-reporter, and methods for using NE neurons obtained according to the methods of this disclosure.

The present invention relates to iPSC produced from fibroblast obtained from a subject affected by a neurodevelopmental disorder entailing intellectual disability (ID) and/or a disorder belonging to the Autism Spectrum Disorder (ASD) and/or Schizophrenia (SZ) and uses thereof. The present invention also relates to a cortical neural progenitor cell or a terminally differentiated cortical glutamatergic or gabaergic neuronal cell or a neural crest stem cell line, a mesenchymal stem cell line produced from the iPSC or iPSC line. The invention also relates to method for identifying a compound for the treatment and/or prevention of a neurodevelopmental disorder entailing intellectual disability (ID) and/or a disorder belonging to the Autism Spectrum Disorder (ASD) and/or Schizophrenia (SZ) and to a LSD1 inhibitor or a HDAC2 inhibitor for use in the treatment of such disorders.